Table 2.

Differences in Medical Therapy Over Time Between Treatment Groups

	NT-proBNP- guided (n=446)		Usual Care (n=448)		p- value*
	Baseline	12 mo.	Baseline	12 mo.
Beta-Blocker
% taking beta-blocker	93%	91%	93%	91%	0.86
Mean dose achieved (% of target dose)	33%	48%	35%	45%	0.60
Proportion at 50% of target dose	37%	60%	33%	57%	0.97
Proportion at 100% of target dose	7%	15%	6%	11%	0.31
ACE/ARB
% taking ACE/ARB	77%	75%	74%	71%	0.63
Mean dose achieved (% of target dose)	41%	55%	43%	53%	0.35
Proportion at 50% of target dose	41%	51%	41%	49%	0.74
Proportion at 100% of target dose	17%	31%	20%	27%	0.11
MRA
% taking MRA	50%	54%	48%	52%	1.00
Mean dose achieved (% of target dose)	98%	115%	94%	103%	0.29
Proportion at 50% of target dose	98%	99%	100%	99%	0.42
Proportion at 100% of target dose	76%	85%	75%	75%	0.06
Loop Diuretics
Mean dose (mg furosemide equivalents)†	77	86	76	77	0.26

^*p-value is for comparison of change over time in NT-proBNP guided group compared to change over time in usual care group

Abbreviations: ACE/ARB, angiotensin-converting enzyme/angiotensin receptor blocker; BB, beta-blocker; MRA, mineralocorticoid receptor antagonist; NT-proBNP-guided, amino-terminal pro–B-type natriuretic peptide